Pipeline

October 7, 2019

Company	Drug/Device	Medical Condition	Status
Themis Bioscience and ZIKAVAX	Second-generation Zika vaccine	Zika virus	Phase 1 study initiated enrolling 48 healthy subjects
Noveome Biotherapeutics, Inc.	ST266	intraocular hypertension	Phase 1 trial initiated enrolling subjects at the University of Pennsylvania who have been diagnosed with intraocular hypertension who have not yet developed optic nerve damage
Clover Biopharmaceuticals	SCB-313	malignant ascites	Phase 1 trial initiated enrolling subjects in China
Oncternal	Cirmtuzumab in combination with Ibrutinib	Mantel cell lymphoma (MCL)	Phase 1b expansion cohort trial initiated to confirm the RDR
AVEO Oncology AstraZeneca	Tivozanib (FOTIVDA) and Durvalumab (IMFINZI)	hepatocellular carcinoma (HCC)	Phase 1b/2 trial initiated enrolling 50 subjects with hepatocellular carcinoma (HCC) who have not received prior systemic therapy
Checkmate Pharmaceuticals Inc.	CMP-001 in combination with BAVENCIO (avelumab), utomilumab (4-1BB agonist) and PF-04518600 (OX40 agonist)	Squamous Cell Carcinoma of the Head and Neck (SCCHN)	Phase 1b/2 trial initiated enrolling 60 subjects with Squamous Cell Cancer of the Head and Neck (SCCHN)
Adrenomed	Adrecizumab	septic shock	Phase 2 trial initiated enrolling 300 subjects with early septic shock and elevated blood levels of Adrenomedullin
Oncopeptides AB	melflufen with dexamethasone	relapsed/refractory multiple myeloma (RRMM)	Phase 2 trial initiated enrolling 150 subjects
North Sea Therapeutics	Icosabutate	NASH (Non-alcoholic Steatohepatitis)	Phase 2b trial initiated enrolling 264 subjects
Immutep	eftilagimod alpha (“efti” or “IMP321”) with MSD’s KEYTRUDA(R) (or pembrolizumab, an anti-PD-1 therapy)	Non-small cell lung cancer (NSCLC)	Phase 2 expansion cohort trial initiated enrolling 19 subjects with second line head and neck squamous cell carcinoma or non-small cell lung cancer in first and second line in 13 study centers across the U.S., Europe and Australia
Cortexyme	COR388	Alzheimer’s Disease	Phase 2/3 trial initiated enrolling 570 subjects in U.S. and Europe
Incyte	ruxolitinib cream	vitiligo	Phase 3 trial initiated enrolling 300 adolescent and adult subjects ages 12 and older who have been diagnosed with non-segmental vitiligo
Galmed Pharmaceuticals Ltd.	SCD1 modulator Aramchol	nonalcoholic steatohepatitis ("NASH") and fibrosis	Phase 3/4 trial initiated enrolling 2,000 subjects with NASH and fibrosis stages 2-3 who are overweight or obese and have prediabetes or type 2 diabetes at 185 sites in the U.S., Europe, Latin America and Asia.
Luminex Corporation	ARIES MRSA Assay	methicillin-resistant Staphylococcus aureus (MRSA)	510 (k) clearance granted by the FDA
Exogenesis Corporation	Exogenesis Hernia Mesh	soft tissue repair, abdominal wall hernias and abdominal wall deficiencies	510 (k) clearance granted by the FDA
(LAS) Laser Associated Sciences	FlowMet-R	peripheral artery disease (PAD)	510 (k) clearance granted by the FDA
Janssen Pharmaceuticals	INVOKANA (canagliflozin)	Heart failure in patients with type 2 diabetes (T2D) and DKD	Approval granted by the FDA
Janssen Pharmaceuticals	Darzalex	multiple myeloma	Approval granted by the FDA
AbbVie	MAVYRET (glecaprevir/pibrentasvir)	naïve chronic hepatitis C (HCV) with cirrhosis or with compensated cirrhosis	Approval granted by the FDA
Genentech	Rituxan (rituximab) injection	granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA) in children 2 years of age and older in combination with glucocorticoids (steroid hormones)	Approval granted by the FDA